Last edition
News about "Lundbeck "
Lundbeck's Asedebart Receives EU Orphan Designation for Cushing's Syndrome
Lundbeck’s asedebart receives orphan designation in the European Union for Cushing’s syndrome, supporting its development as a potential targeted therapy for ACTH-driven endocrine disorders.
Lundbeck | 25/08/2026 | By News Bureau
Lundbeck's Oral Narcolepsy Drug Candidate Receives FDA Fast Track Designation
Lundbeck has received FDA Fast Track designation for Lu AH69593, its investigational oral orexin 2 receptor agonist, accelerating the development of a potential new treatment for patients living with narcolepsy.
Lundbeck | 27/07/2026 | By News Bureau
Lundbeck Secures Orphan Drug Designation in Japan for Asedebart Targeting Rare Endocrine Disorders
Lundbeck has received orphan drug designation in Japan for asedebart, an investigational ACTH-targeting therapy being developed for congenital adrenal hyperplasia and Cushing’s disease.
Lundbeck | 18/05/2026 | By News Bureau | 117
Lundbeck to Acquire Longboard Pharmaceuticals to Expand its Neuroscience Pipeline
Under the terms of the agreement, Lundbeck will commence a tender offer for all outstanding shares of Longboard common stock, whereby Longboard shareholders will be offered a payment of USD 60.00 per share in cash.
Lundbeck | 15/10/2024 | By Aishwarya | 893
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy